Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/11/2025

Gastrointestinal Stromal Tumors (GISTs) Diagnosis and Characteristics

Epidemiology and Diagnosis

  • The stomach accounts for 60% of all GIST cases, making it the single most common anatomic location for these tumors 1, 2, 3
  • Spindle cell morphology represents 70% of all GISTs, making it the predominant histologic pattern 1, 4, 5
  • The National Comprehensive Cancer Network recommends that when a spindle cell neoplasm is encountered in the stomach, GIST should be the leading diagnostic consideration given this dual predominance 1, 2

Diagnostic Algorithm

  • The American College of Pathology recommends performing KIT (CD117) immunostaining first, as 95% of GISTs are positive for KIT and/or DOG1 1, 4, 3
  • If KIT is positive in a spindle cell tumor with compatible morphology, this strongly supports GIST 1, 4
  • The College of American Pathologists suggests that KIT positivity alone is not sufficient—morphologic features must be compatible with GIST 1
  • The World Health Organization recommends performing DOG1 staining when KIT is negative, as approximately 5% of GISTs are KIT-negative but DOG1-positive 1, 4, 5
  • CD34 staining can provide supportive evidence, as 70% of GISTs are CD34-positive 1, 3

Exclusionary Markers

  • Desmin positivity suggests myogenic tumors (leiomyoma/leiomyosarcoma) rather than GIST 1, 4, 6
  • S-100 positivity suggests schwannoma, which can also present as a gastric spindle cell tumor 1, 4
  • True gastric leiomyomas are rare and would show both smooth muscle actin and desmin positivity 6

Molecular Confirmation

  • The European Society for Medical Oncology recommends mutation testing for KIT and PDGFRA genes, as nearly 80% and 10% of GISTs harbor these mutations respectively 1, 5, 7
  • Most KIT mutations occur in exon 11 (65%), followed by exon 9 (8%) 5, 7
  • For gastric GISTs without KIT or PDGFRA mutations, the National Institute of Health recommends performing SDHB immunostaining to identify SDH-deficient GISTs 1, 5

Clinical Considerations

  • Approximately 5% of GISTs are KIT-negative, requiring DOG1 and potentially genetic testing for definitive diagnosis 1, 4
  • Consultation with a sarcoma pathologist is recommended when diagnostic concordance cannot be achieved, as GIST is a rare disease with diagnostic challenges 4, 5
  • Small "mini-GISTs" (less than 10 mm) are commonly found incidentally in the proximal stomach of individuals over 50 years and are typically biologically indolent unless they show high-risk features 1, 2